Modeling neuronal defects associated with a lysosomal disorder using patient-derived induced pluripotent stem cells.

@article{Lemonnier2011ModelingND,
  title={Modeling neuronal defects associated with a lysosomal disorder using patient-derived induced pluripotent stem cells.},
  author={Thomas Lemonnier and Stéphane Blanchard and Diana Toli and Elise Roy and St{\'e}phanie Bigou and Roseline Froissart and Isabelle Rouvet and Sandrine Vitry and Jean Michel Heard and Delphine Bohl},
  journal={Human molecular genetics},
  year={2011},
  volume={20 18},
  pages={
          3653-66
        }
}
By providing access to affected neurons, human induced pluripotent stem cells (iPSc) offer a unique opportunity to model human neurodegenerative diseases. We generated human iPSc from the skin fibroblasts of children with mucopolysaccharidosis type IIIB. In this fatal lysosomal storage disease, defective α-N-acetylglucosaminidase interrupts the degradation of heparan sulfate (HS) proteoglycans and induces cell disorders predominating in the central nervous system, causing relentless progression… 

Figures from this paper

Delineating the neuropathology of lysosomal storage diseases using patient-derived induced pluripotent stem cells.

This review highlights the information assembled from patient-derived iPSCs on neurodevelopmental and neuropathological defects identified in LSDs and discusses the therapeutic applications such as drug discovery, repurposing of drugs, synergistic effects of Drugs, targeted molecular therapies, gene therapy, and transplantation applications of mutation corrected lines identified using patient- derived iPSC for different LSDs.

Induced pluripotent stem cell models of lysosomal storage disorders

How iPSCs have illuminated the role of lysosomes in more common disorders is discussed, and how models of these rare diseases could contribute to an enhanced understanding of more common neurodegenerative disorders such as Parkinson’s disease are discussed.

Murine neural stem cells model Hunter disease in vitro: glial cell-mediated neurodegeneration as a possible mechanism involved

Evidence supports IDS-ko NSCs as a reliable in vitro model of the disease, and suggests the rescue of PDGFR-α+ glial cells as a therapeutic strategy to prevent neuronal degeneration.

Induced Pluripotent Stem Cells to Understand Mucopolysaccharidosis. I: Demonstration of a Migration Defect in Neural Precursors

A hitherto unknown connection between lysosomal degradation, gene expression and neural motility, which might account at least in part for the phenotype of MPS1-H patients is demonstrated.

Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type A

The NPA neural stem cells possess the characteristic NPA disease phenotype that can be ameliorated by tocopherols, cyclodextrin, and ASM and are used as a new cell‐based disease model for further study of disease pathophysiology and for high‐throughput screening to identify new lead compounds for drug development.

Ex vivo gene therapy for lysosomal storage disease using IPSC-derived neural stem cells

Ex vivo NSC gene therapy may be a viable option for many lysosomal storage diseases using easily attainable, non-neural patient tissue using recently developed induced pluripotent stem cell (iPSC) technologies.

Human iPSC-based models highlight defective glial and neuronal differentiation from neural progenitor cells in metachromatic leukodystrophy

This study points to MLD iPSC-derived neural progeny as a useful in vitro model to assess the impact of ARSA deficiency along NPC differentiation into neurons and glial cells, with important therapeutic implications.
...

References

SHOWING 1-10 OF 68 REFERENCES

Induced pluripotent stem cells from a spinal muscular atrophy patient

This is the first study to show that human induced pluripotent stem cells can be used to model the specific pathology seen in a genetically inherited disease and represents a promising resource to study disease mechanisms, screen new drug compounds and develop new therapies.

Modeling Pathogenesis and Treatment of Familial Dysautonomia using Patient Specific iPSCs

The derivation of patient-specific FD-iPSCs and the directed differentiation into cells of all three germ layers including peripheral neurons are reported, illustrating the promise of iPSC technology for gaining new insights into human disease pathogenesis and treatment.

GAP43 overexpression and enhanced neurite outgrowth in mucopolysaccharidosis type IIIB cortical neuron cultures

It is indicated that heparan sulfate oligosaccharide storage modifies GAP43 expression in MPSIIIB cortical neurons with potential consequences for neurite development and neuronal functions that may be relevant to clinical manifestations.

Functional abnormalities of heparan sulfate in mucopolysaccharidosis-I are associated with defective biologic activity of FGF-2 on human multipotent progenitor cells.

It is demonstrated here that abnormally sulfated HS in Hurler multipotent progenitor cells perturb critical FGF-2-FGFR1-HS interactions, resulting in defective FGF -2-induced proliferation and survival of Hurler multi-progenitor cells.

Attenuated plasticity in neurons and astrocytes in the mouse model of Sanfilippo syndrome type B

The results showed important alterations in the expression of several genes involved in the maintenance of neuroplasticity in the MPS III B, which in turn may result in reduction of neuronal health and brain function.

Early Neurodegeneration Progresses Independently of Microglial Activation by Heparan Sulfate in the Brain of Mucopolysaccharidosis IIIB Mice

The results support the view that neurodegeneration is primarily cell autonomous in this pediatric disease and indicate priming of microglia by HS oligosaccharides through the TLR4/MyD88 pathway.

Generation of human-induced pluripotent stem cells

This protocol describes how to establish primary human fibroblasts lines and how to derive iPS cells by retroviral transduction of reprogramming factors, and takes 2 months to complete reprograming human primary fibro Blasts starting from biopsy.

Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy

Sanfilippo syndrome type B (mucopolysaccharidosis III B, MPS III B) is an autosomal recessive, neurodegenerative disease of children, characterized by profound mental retardation and dementia. The
...